<scp>RBC</scp> alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?

Lee, Edward S.; Hendrickson, Jeanne E.; Tormey, Christopher A.

doi:10.1111/trf.16736

Cited by 3 publications

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The effectiveness of daratumumab itself in these patients is unclear. While it does seem plausible that daratumumab was at least partially responsible for the disappearance of a portion of the alloantibodies, prior authors have shown that albeit uncommon, new antibodies can occur (2), and existing alloantibodies can persist despite daratumumab treatment (3)(4)(5)(6). Secondly, the authors fail to acknowledge the possibility that the alloantibodies may have disappeared naturally through the phenomenon of evanescence.…”

Section: Discussionmentioning

confidence: 98%

Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

et al. 2023

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 98%

Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

et al. 2023

View full text Add to dashboard Cite

Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method

Safić Stanić,

Kruhonja Galić,

Lukić

et al. 2024

Transfusion and Apheresis Science

View full text Add to dashboard Cite

Interference of Monoclonal Antibody Therapy in Transfusion: An Update

Solves Alcaina,

Asensi Cantó

2024

Hemato

View full text Add to dashboard Cite

Monoclonal antibody (MoAb) therapy has been increasingly used in recent years for hematologic malignancies. The MoAbs anti-CD38 and anti-CD47 are immunoglobulins directed against epitopes that are highly expressed not only on cancer cells, but also on red blood cells (RBCs), as well as platelets. Additionally, producing an off-target effect interferes in pre-transfusion testing, having the potential to unchain hemolytic anemia. Blood banks must assure the availability and safety of blood products for patients in need. Thus, MoAbs have become a challenge for blood banks, since methods to overcome interferences must be adopted. Several strategies have been proposed to mitigate pan-reactivity in pre-transfusion indirect antiglobulin tests, such as the treatment of reagent RBCs with enzymes or reducing agents, allogeneic RBC adsorptions, and drug-specific neutralization assays. All of these have some kind of limitation. This review summarizes the interferences of MoAbs in pre-transfusion testing, focusing on the available strategies to mitigate them in order to provide a safe transfusion.

show abstract

RBC alloimmunization and daratumumab: Are efforts to eliminate interferences and prevent new antibodies necessary?

Abstract: See article on page 3468–3472, in this issue

Cited by 3 publications

References 18 publications

Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Commentary: Case report: Daratumumab treatment in pre-transplant alloimmunization and severe hemolytic anemia

Risk of new alloimmunization in patients on anti-CD38 treatment using tube LISS-IAT method

Interference of Monoclonal Antibody Therapy in Transfusion: An Update

Contact Info

Product

Resources

About